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Abstract
The chemical structure of quinazolinones includes benzene ring fused with 
2-pyrimidinone (1), 4-pyrimidinone (2) or 2,4-pyrimidinedione (3) ring, and are 
named as quinazolin-2(1H)-one, quinazolin-4(3H)-one or quinazolin-2,4(1H, 
3H)-one, respectively. The chemical structure of quinazolinones constitutes a 
crucial scaffold of natural and synthetic compounds with various therapeutic and 
biological activities. Quinazolinones are first synthesized by Stefan Niementowski 
(1866–1925) and named after Niementowski quinazolinone synthesis. 
Quinazolinones have strongly attracted the interest of medicinal chemist as they 
constitute a large class of compounds that exhibited broad spectrum of biological 
activities including antimicrobial, antimalarial, anticonvulsant, anticancer, anti-
leishmanial, anti-inflammatory, etc. This chapter provides a brief overview on the 
recent advances on chemical and pharmacological aspects of quinazolinone deriva-
tives published in the last decade.
Keywords: quinazolinones, antimicrobial, antimalarial, anticancer
1. Introduction
Heterocyclic compounds are organic cyclic compounds having at least one atom 
other than carbon in their ring structures. Quinazolinones are formed by fusion of 
benzene ring with 2-pyrimidinone (1), 4-pyrimidinone (2) or 2,4-pyrimidinedi-
one (3) ring, and are named as quinazolin-2(1H)-one, quinazolin-4(3H)-one or 
quinazolin-2,4(1H, 3H)-one, respectively (Figure 1).
Quinazolinones are pharmacophoric scaffold ubiquitous in various biologi-
cally active natural products, synthetic compounds, pharmaceutical drugs, 
agrochemicals and veterinary products [1]. The chemical structure of quinazo-
linones constitute a crucial scaffold of compounds with various therapeutic and 
biological activities such as antimalarial [2], antimicrobial [3, 4], antitubercular 
[5], anticonvulsant [6], anticancer [7], antihypertensive [8], anti-diabetic [9], 
anti-inflammatory [10], anti-cholinesterase [11], cellular phosphorylation 
inhibition [12], dihydrofolate reductase inhibition [13], kinase inhibitory activi-
ties [14], inhibitors of tubuline polymerization [15], diuretic [16], antipsychotic 
[17], dopamine agonists [18] and anti-HIV [19]. Quinazolinones (Figure 1) is 
a core scaffold for the structure of more than 200 naturally occurring alkaloids 
isolated from different plant families and from various microorganisms such as 
Bacillus cereus, Peganum nigellastrum, Dichroa febrifuga and Bouchardatia neuro-
cocca [20]. Depending on the position of the keto group, they can be classified 
into three types. Among the 2(1H)-quinazolinones (1), 4(3H)-quinazolinones 
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and 2,4(1H,3H)-quinazolinediones (2), 4(3H)-quinazolinones (3) are most 
prevalent and significant in medicinal chemistry possessing a multitude of 
pharmacological actions [21]. Quinazolinones are generally classified into four 
classes, 2-substituted quinazolinones, 3-substituted quinazolinones, 2,3-disub-
stituted quinazolinones and quinazolinone derivatives including fused quinazo-
linones [22].
2. Synthetic methods of quinazolinones
The number of synthetic methods of quinazolinone cores has intensely 
increased from year to year. These advancements in methods of synthesis lead to the 
access to new and effective quinazolinone compounds with augmented structural 
diversity starting from affordable and easily accessible substrates. In this chapter, 
we depict different methods of synthesis of quinazolinone derivatives from cheap 
and readily available starting precursors.
2.1 Synthesis of quinazolinone compounds from 2-aminobenzoic acid
Quinazolin-4(3H)-one (4) was synthesized by the reaction of formamide with 
2-aminobenzoic acid at 125–130°C and cyclization of 2-aminobenzoic acid takes 
place as described in Figure 2 [23]. Synthetic works started from esterification 
of 2-aminobenzoic acid and subsequently followed by reaction with isocyanates 
afforded 1,3-disubstituted quinazol-2,4(1H, 3H)-diones (5) [24] (Figure 2). 
2-mercapto-3-substituted quinazolin-4(3H)-one derivatives (6) (Figure 2) have 
been synthesized through the interaction between 2-aminobenzoic acid and cor-
responding isothiocyanate reagent.
In 1960, Ried et al. reported [25–27] the reaction of imidates and 2-aminoben-
zoic acid in methanol at 80°C to afford the desired quinazolinones (7) in good yields 
(Figure 2).
A recently reported route, to the synthesis of 2-substituted quinazolin-4(3H)-
ones (7) under microwave conditions was reported by Rad-Moghadam and Mohseni 
[28]. This approach involves the condensation of 2-aminobenzoic acid, orthoesters 
and ammonium acetate which afford the 2-substituted-4(3H)-quinazolinone (7) 
Figure 2.
A solvent-free approach was reported by Li et al. [29] for the synthesis of 
2,3-disubstituted-4(3H)-quinazolinones (8). The approach involves the interaction 
between 2-aminobenzoic acid, acyl chlorides and aromatic/aliphatic amines in the 
presence of SO3H-functionalized Brønsted acid ionic liquids as a catalyst under 
microwave irradiation (Figure 2). Langer and Döring [30] reported the reaction of 
2-aminobenzoic acids with oxalic acid bis(imidoyl) chlorides to prepare quinazoli-
nones (9) Figure 2.
Figure 1. 
Quinazolinone and quinazolinedione structures.
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2.2 Synthesis of quinazolinone compounds from 2-aminobenzamide
In 1962, Bake and Almaula [31] have reported the synthesis of 2-carboethoxy-
quinazoline-4(3H)-one 10 through the reaction of anthranilamide and diethyl oxa-
late (Figure 3). Shaterian and Rigi [32] reported a starch sulfate-catalyzed method 
for synthesis of 2-substituted-1,2,3,4-tetrahydro-4-quinazolinones 11 (Figure 3). 
Zhang and co-workers [33] reported a MnO2-catalyzed method for the synthesis of 
2-substituted quinazolinones 12. Anthranilamides undergo a-MnO2-catalyzed oxi-
dative cyclization with alcohols using TBHP as an oxidant (Figure 3). Compound 
12 could be obtained through the condensation of anthranilamide with an aldehyde 
in refluxing ethanol in the presence of CuCl2 [34]. Schiff base intermediate was 
first obtained and, in turn, is transformed into the 2-substituted quinazolinones 12 
(Figure 3).
In 1887, when Körner reported that the acylation of anthranilamide results in 
diamide intermediate which upon treatment with sodium carbonate or sodium 
hydroxide yielded 2-phenylquinazolin-4(3H)-one 12 (Figure 3) [35].
Quinazolin-4(3H) one compound 12 have been developed by Yang et al. via 
selective cleavage of the triple bond of ketoalkynes. A reasonable mechanism was 
suggested for this reaction (Figure 3). Michael addition of the amino group of 
the anthranilamide to the triple bond of the ketoalkyne generated the enaminone 
Figure 2. 
Synthesis of quinazolin-4(3H) one from 2-aminobenzoic acid.
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intermediate which upon acid catalyzed intramolecular cyclization with subsequent 
C-C bond cleavage afforded final product 12.
2.3 Synthesis of quinazolinone compounds from o-substituted aniline
Yan et al. [36] reported a C(sp3)-H oxidative amination, tandem condensa-
tion oxidation, catalyzed by iodine method to access quinazolinone compound 13 
(Figure 4).
Natte and co-workers [37] reported the reaction of 2-iodoanilines, amines and 
trimethyl orthoformate catalyzed by Pd/C afforded quinazolin-4(3H) one com-
pounds 13 (Figure 4).
Figure 3. 
Synthesis of quinazolin-4(3H) one from 2-aminobenzamide.
Figure 4. 
Synthesis of quinazolinone compounds from o-substituted aniline.
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Mizuno et al. [38] synthesis of qiunazolin-2,4-(1H,3H) ones (2,4-dihydroxy-
quinazolines) 15 using 2-aminobenzonitriles starting materials in the presence 
of carbon dioxide and suitable base. The reaction first generates the carbamate 
salts followed by nucleophilic cyclisation via attack of the carbamate oxygen 
onto the cyano group with subsequent rearrangement into an intermediate that 
is protonated yielding the desired 2,4-dihydroxyquinazoline 15 (Figure 4). Also, 
amidation of anthranilamide with 3-phenylacryloyl chloride with subsequent 
oxidative ring closure using base catalyst revealed 2-styryl-4(3H) quinazolinone 
16 (Figure 4) [39].
2.4 Synthesis of spiroquinazolinones
Revathy and Lalitha [39] reported a method of p-Toluene sulfonic acid-catalyzed 
synthesis of spiroquinazolinones 17 using anthranilamide and with ketones as start-
ing materials (Figure 5). Tajbakhsh et al. [40] reported a H3PO3-catalyzed method 
for synthesis of spiro2,3-dihydroquinazolin-4(1H)-ones 18 using isatoic anhydride, 
hydrazides and cyclic ketones, in the presence of H3PO3 catalyst (20 mol %, in 
ethanol) (Figure 5).
2.5 Synthesis of heterocycle-fused quinazolinones
Yang et al. [41] reported the synthesis of tricyclic quinazolinones 19 using 
formic acid-catalyzed intramolecular cyclization of 3-(2-aminoalkyl)-2-
(phenylamino) quinazolin-4(3H)-ones (Figure 6).
Reddy et al. [42] reported a CuI/DMSO-catalyzed domino oxidative method for 
the synthesis of tryptanthrin compound 20 through the interaction of 2-aminoace-
tophenone and isatoic anhydrides (Figure 6).
Foldesi et al. [43] reported the synthesis of the tetracyclic pyrrolotriazepino-
quinazolinone derivative 21 the interaction between 1-aryl-4-(methylsulfanyl)-5H-
pyrrolo[2,1-d] [1, 2, 5] triazepines and anthranilic acid under reflux in acetic acid 
(Figure 6).
Yuan et al. [44] developed a process to prepare 1H-pyrimido[2,1-b]quinazoline-
2,6-dione derivatives 22. The product was accessed through a tandem aza-Wittig/
nucleophilic addition/intramolecular cyclization/isomerization reaction of 
(E)-methyl 2-((2-azidobenzamido)methyl)-3-phenylacrylate with triphenylphos-
phine and isocyanates (Figure 6).
Wang and Ganesan [45] reported the synthesis of luotonin A, 23 through the 
reaction of anthranilic acid with 1H-pyrrolo[2,3-b]quinolin-2(3H)-one (Figure 6).
Figure 5. 
Synthesis of spiroquinazolinones.
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3. Biological applications of quinazolinones
Natural quinazolinones that widely used in traditional folk medicines are 
isolated from the plants and microorganisms while the major quinazolinone 
derivatives are accessed through synthetic process by some chemical reactions. 
Quinazolinone compounds constitute most privileged class of biologically active 
heterocyclic compounds. Because of their wide spectrum of biological activities, 
quinazolinones either from natural source or from synthetic origin, have prompted 
the medicinal chemist for structural design of these active compounds to develop 
high selective and potent pharmacological activities.
3.1 Anticancer activity
The natural cytotoxic quinazolinones are depicted in Figure 7. The Chinese 
herbal medicinal plant, Luotonin A 23, Figure 7 is a cytotoxic natural alkaloid pos-
sessing pentacyclic fused-quinazolinone moiety. It was first isolated from Peganum 
migellastrum in 1997 and it is in clinical use as anticancer agent and showed low 
human human topoisomerase-I inhibitor activity [46].
Topoisomerases being major targets for anticancer drug design, the luotonin A 
was used as a lead compound for development of analogs with increased potency 
[47]. In comparison with the luotonin A, the majority derivatized analogs explored 
higher activity for topoisomerase I inhibition and better in vitro cytotoxicity than 
lutonin A [47]. In view of these results, luotonin A is considered as a pharmacoph-
oric core for the design of new topoisomerase I inhibitors [48].
In 2006, (−)-chaetominine 24, a tetracyclic tripeptide alkaloid (Figure 7) 
was isolated from an endophytic fungus, Chaetomium sp. IFB-E015, and showed 
smaller IC50 than the most frequently prescribed anticancer drug 5-fluorouracil 
Figure 6. 
Synthetic methods of heterocycle-fused quinazolinones.
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against human leukemia K562 (IC50 21 μM) and colon cancer SW1116 (IC50 
28 μM) cell lines with IC50 values [49].
Quinazolinone alkaloids, auranomides A–C (25–27) were isolated from 
Penicillium aurantiogriseum and showed moderate cytotoxicity against human 
tumor cells [50]. Sartorymensin (28), a hexcyclic indoloazepine-fused quinazo-
linone derivative was isolated from Neosartorya siamensis fungus (KUFC 6349) 
showed a moderate in vitro growth inhibitory activity of several cancer cell lines 
[51]. The 2-substituted quinazolinone alkaloid, bouchardatine (29), isolated from 
Bouchardatia neurococca (Rutaceae), showed anti-cancer effects [52]. The aurantio-
mides B and C (30, 31) isolated from Penicillium aurantiogriseum fungus derived 
from sponge and showed moderate activities (IC50 values of 52–54 μg/mL against 
HL-60 and P-388 for aurantiomide B and IC50 values of 48–62 μg/mL against P-388 
and BEL-7402 for aurantiomide C) [53].
Mahdavi et al. [54] developed a new N-substituted 2-arylquinazolinones bearing 
transstilbene moiety 32 showed good profile (IC50 < 5 μM) against human ductal 
breast epithelial tumor (T-47D) and human breast adenocarcinoma (MCF-7 and 
MDA-MB-231) showing two-fold potency more than etoposide standard drug. 
2-(piperazin-1-yl-methyl)quinazolin-4(3H)-one (33, R = Acetyl, Propionyl) 
showed potent anti-cancer activity [55]. While, 3-(2-chloro benzylidinamine)-
2-(furan-2-yl)quinazoline-4(3H)-one (34) showed high activity against ovarian 
Figure 7. 
Chemical structure of anticancer compounds.
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and non-small cell lung cancer [56]. 7-chloro-3-{[(4-chlorophenyl)methylidene]
amino}-2-phenylquinazolin-4(3H)-one (35), explored significant activity against 
CNS Cancer cell line [57].
Zayed et al. [58] developed a quinazolinone-bearing sulphonamide moiety 
compound 36 which upon MTT ass showed IC50 value of 2.51 μM, whereas, the 
reference drug (methotrexate) exhibited an IC50 value of 2.4 μM, against Michigan 
Cancer Foundation-7 (MCF-7) breast cancer cells, National Cancer Institute (NCI) 
lung cancer cells and Human Embryonic Kidney-293 (HEK-293) normal kidney 
cell. 6-Substituted quinazolinone compound 37 was reported by Malinowski et al., 
revealed significant activity toward both HT29 (IC50 = 50.90 μM) and HCT116 
(IC50 = 46.00 μM) cells lines [59].
Ahmed and Belal reported 2-furylquinazolinone derivatives including com-
pound 38 that explored IC50 value equal to 7 μM/mL on MCF7 cells, and promising 
inhibitory activity against EGFR-TK [60], and compound 39 depicted a 24-fold 
higher potency than doxorubicin on HCT116 cancer cells, with IC50 values of 
0.2 nmol/mL. Also, compound 39 showed a similar potency to the doxorubicin on 
MCF7 cell lines and remarkable EGFR inhibitor activity compared with erlotinib 
standard drug [61].
3.2 Anti-inflammatory activity
The inflammation is a biochemical reactions response that protects the body 
from infection and injury. It reflects the response of the organism to various stimuli 
and is related to many disorders such as arthritis, asthma and psoriasis which 
require prolonged or repeated treatment. The major cause of inflammation the 
release of chemicals from tissues such as the prostaglandins, histamine, leukot-
rienes, bradykinin, platelet-activating factor and interleukin-1. Corticosteroids 
inhibit the synthesis of both PGs and LTs through the release of lipocortin, which 
inhibits phospholipase A2 and subsequently reduces arachidonic acid release 
alleviating the inflammation of either rheumatoid arthritis or asthma. While 
nonsteroidal anti-inflammatory drugs NIASID relieve the inflammation through 
the inhibition of the cyclooxygenase enzyme and reducing the synthesis of pros-
tanoids [62]. Figure 8 shows the chemical structure of the anti-inflammatory 
quinazolinone compounds. Spiro [(2H,3H) quinazoline-2,10-cyclohexan]-4(1H)-
one compounds 40 and 41 were reported as potent anti-inflammatory and analgesic 
activity of superior GIT safety margin in rats model compared with indomethacin 
(10 mg/kg) and tramadol (20 mg/kg) as reference standards [63].
Abbas SE et al. [64] reported a new quinazolinone-pyrimidine hybrid com-
pound (42) which showed more activity and less ulcerogenicity than diclofenac 
(IC50 = 116.73 μmol/kg; ulcer index = 11.38). The compound explored two-fold 
more selective inhibition of COX-2 than COX-1.
Hemalath K et al. [65] reported a novel quinazolinone derivative (43) that 
explored 36.3 inhibition of oedema in animal model and showed anti-inflammatory 
activity as same as phenyl butazone reference drug at a p.o. dose of 25, 50, and 
100 mg/kg. Hemalath K et al. [65] also developed a 2,3-dihydroquinazolin-4(1H)-
one (44) succeeded to produce higher protection against bovine serum albumin 
(BSA) denaturation that displayed higher protection than diclofenac sodium refer-
ence drug. Manivannan et al. [66] designed new quinazolinone derivatives (45; 
R1 = H, Br, R2 = H, Cl; R3 = H, OCH3) and assayed the derivatives for cyclooxygen-
ase inhibitions by ovine COX and carrageenan-induced rat paw oedema methods. 
Four compounds showed potent anti-inflammatory activity with oedema inhibition 
percentage of 49 ± 1.16, 45 ± 0.82, 46 ± 1.36 and 54 ± 1.83 using indomethacin drug 
as reference.
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Mohamed MS et al. [67] have synthesized a series of 2-phenyl-4(3H) quinazoli-
none derivatives of which to compounds (46, 47) showed considerable potent anti-
inflammatory activity in rats model with oedema inhibition percentage of 46 ± 1.26, 
43 ± 1.82 using indomethacin standard drug in 3 hrs.
Rakesh et al. [68] have synthesized a series of Schiff base derivatives of quin-
azolinone and got excellent anti-inflammatory activity for synthesized compounds 
(48; n = 2,3, R = Cl, NO2).
3.3 Anticonvulsant activity
Epilepsy is defined a chronic neurological syndromes and marked by neuronal 
firing and neuronal hyperexcitability. Although, the available antiepileptic thera-
peutics explore satisfactory seizure control in about 70% of epileptic patients, it has 
become very urgent to search for new antiepileptic compounds with fewer side-
effects and less toxicity.
Figure 9 shows chemical structures of anticonvulsant agents. The structure-
activity relationship of the anticonvulsant activity of 4(3H)-quinazolinones nucleus 
revealed the crucial role of a methyl group at position 2 and a substituted aromatic 
ring at position 3 for the anticonvulsant activity of compounds such as methaqualone 
(49; R1 = CH3, R2 = o-tolyl, R3 = H), etaqualone (49; R1 = CH3, R2 = 2-ethylphenyl, 
R3 = H), mecloqualone (49; R1 = CH3, R2 = o-chlorophenyl, R3 = H), methyl-
methaqualone (49; R1 = CH3, R2 = 2,4 = dimethylphenyl, R3 = H), piriqualone (49; 
R1 = CH3, R2 = ((E)-2-pyridin-2-ylethenyl), R3 = H) and afloqualone (49; R1 = fluo-
romethyl, R2 = o-tolyl, R3 = NH2) [69]. Against electroshock induced convulsions 
methaqualone is 1.5 times more potent anticonvulsant than phenytoin sodium and 
Figure 8. 
Chemical structure of anti-inflammatory quinazolinone derivatives.
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against pentylenetetrazol-induced seizures it is 10 times more potent than troxidone 
[70]. Methaqualone produces anticonvulsant effects, through the GABA type A 
receptors, at low doses while at higher doses, it produces muscle-relaxant and seda-
tive effects [71].
Al-Salem et al. [70] reported 4(3H)-quinazolinone bearing hydrazinecarbothio-
amide, benzenesulfonohydrazide or phenylacyl acetohydrazide moiety. Compounds 
50–53 were most potent with 100% protection against PTZ-induced convulsions 
compared with the reference drug sodium valproate. Abuelizz HA et al. [72] syn-
thesized a of 6,8-diiodo-2-methyl-3-substituted-quinazolin-4(3H)-ones analogues 
(54; R = Cl, Br, F) that revealed good anticonvulsant activity as evaluated by the 
maximal electroshock-induced seizure and subcutaneous pentylenetetrazole tests.
A series of novel 3-[5-substituted phenyl-1,3,4-thiadiazole-2-yl]-2-styryl 
quinazoline-4(3H)-one derivatives has been synthesized by Jatav et al. [73]. Of this 
series, compounds 55 and 56 revealed anticonvulsant activity results at 0.5 and 4 h 
in both MES and scPTZ test models, whereas compound 57 explored anticonvulsant 
activity results at 4 h in MES model and at 0.5 and 4 h in scPTZ model.
3.4 Antimicrobial activity of quniazolinones
2-oxo-azetidinyl-quinazolin-4(3H)-ones (58) possess antimicrobial activ-
ity against S. aureus, B. subtilis, E. coli and C. albicans [74]. 2-Mercapto-3-(4-
chlorophenyl)-6-iodo-3H-quinazolin-4-one derivatives (59–62) were reported to 
show a significant antimicrobial activity and could be useful as lead compounds for 
further design and discovery of more potent antimicrobials [75].
Vani et al. [76] synthesized a series of quinazolin-4(3H)-one-triazole hybrids 
(63–65) quinazolin-4(3H)-one and oxadiazole hybrids (66–68). Compounds 
64–67 showed significant antibacterial activity against all the bacterial strains, 
Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis) and Gram-negative 
bacteria (Escherichia coli, Pseudomonas aeruginosa), while compounds (63, 67, 68) 
showed highest activity against fungal species, Candida albicans and Aspergillus 
niger compared with ciprofloxacin and fluconazole as reference drugs, respectively.
Figure 9. 
Chemical structure of anticonvulsant agents.
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Kohli et al. reported the antimicrobial activity of the derivatives of 4-Oxo-2-
phenylquinazolin-3(4H)-yl-amine (69; R = H, CH3, C2H5) against bacterial strains 
Staphylococcus aureus and Escherichia coli using ampicillin drug reference at a 
concentration 100 μg/ml [77].
Sowjanya et al. [78] reported the synthesis of 2-(Substituted styryl)-quinaz-
oline-4(3H)-ones (70; R = H, CH3, C2H5) as antibacterial agents against bacterial 
strains Bacillus subtilis, Staphylococcus aureus (Gram-positive), Escherichia coli and 
Proteus vulgaris (Gram-negative) using 100 μg/ml of streptomycin and penicillin as 
standard drugs.
El-Hashash et al. [79] reported the synthesis of quinazolinones bearing sulfon-
amide moiety (71–73) as antimicrobial against Gram-positive bacteria S. aureus 
and B. cereus and Gram-negative bacteria S. marcescens and P. mirabilis and as 
antifungal agents against A. ochraceus Wilhelm and P. chrysogenum using ampicillin 
and mycostatin as standards, respectively. Figure 10 shows the chemical structure 
of antimicrobial compounds (58–73).
Figure 10. 
Chemical structure of antimicrobial compounds.
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3.5 Antimalarial activity
Malaria is a parasitic disease caused by Plasmodium species parasite. It is wide-
spread in several regions in Africa, Asia and South America. These parasites have 
developed a drug resistance to almost all the commercially available antimalarial 
drugs. The good antimalarial potency and the less side effects of quinazolinone 
compounds promote the researchers for the development of new antimalarial 
compounds [80].
In 1948, Febrifugine (74), a Chinese traditional herb, has been extracted from 
leaves of Dichroa febrifuga that was found in the garden plant Hydrangea. It has 
50–100 times as antimalarial as quinine in in vivo model. Febrifugine analogues 
WR140085 (75), WR090212 (76), WR146115 (77) were reported as potent anti-
malarial agents. The gastrointestinal side effects of (74) and the macrophage cells 
mediated clearance of (75–77) requested further therapeutic development and 
discovery of new antimalarial drugs [2]. Birhan et al. [81] have synthesized 3-aryl-
2-(substituted styryl)-4(3H)-quinazolinone derivatives (78, 79) as potent antima-
larial agents (Figure 11).
3.6 Antiviral activity
Wang et al. [82] reported quinazolinone derivatives (80, 81) with potent 
antiviral activity against HIV and TMV. Gao et al. [83] have synthesized a series of 
2-aryl- or 2-methyl-3-(substituted benzalamino)-4(3H)-quinazolinone derivatives 
and found that the compounds (82) and (83) exhibit good antiviral activity against 
TMV (Figure 12).
Liu et al. [84] reported a series of 2-pyridinyl-3-substituted-4(3H)-quinazoli-
nones as anti-influenza A virus agents. Of these derivatives, compounds (84–87) 
revealed potent activity (IC50 = 51.6–93.0 μM) better than that of the clinically used 
drug, ribavirin. Also, it was reported that compound (87) could inhibit influenza A 
virus propagation through inhibition of cellular NF-kB pathway, although it was not 
as effective as ribvarin (Figure 12).
3.7 Cathepsin inhibitor activity
Cathepsins B and H are cysteine proteases that plays a major role in cancer 
progression as they degrade extracellular matrices facilitating invasion, angiogen-
esis and metastasis. Therefore the research community has been prompted to the 
discovery of potent cathepsins inhibitor hemotherapeutics [85].
Singh and Raghav [86] reported the synthesis of a series of 2,3-dihydroquin-
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compounds, 2-(4-fluorophenyl)-2,3-dihydroquinazolin-4(1H)-one (88; R = F) and 
2-(4-chlorophenyl)-2,3-dihydro quinazolin-4(1H)-one (88; R = Cl) substituted 
compounds showed maximum inhibition on cathepsin B. Whereas for cathepsin 
H, 2,3-dihydro-2-(4-methylphenyl)quinazolin-4(1H)-one (88; R = Me) and 
2-(4-fluorophenyl)-2,3-dihydroquinazolin-4(1H)-one (88; R = F) have been found 
to be the most potent inhibitors.
Raghav and Singh [87] reported the synthesis of bischalcones and their 
quinazoline-2(1H)-one (89, 90; R = H, NO2, CH3O, (CH3)2N) and quinazoline-
2(1H)-thione (91, 92) derivatives as cathepsin B and cathepsin H inhibitors, 
(Figure 13). Bischalcones and their quinazoline-2(1H)-thione derivative (91, 92; 
R = H, NO2, CH3O, (CH3)2N) inhibited both cathepsins in a competitive manner 
whereas quinazoline-2(1H)-one derivative (89, 90) inhibited both cathepsins in a 
non-competitive manner.
3.8 Topoisomerase inhibitor activity
The DNA replication process is controlled essentially by DNA topoisomerase I 
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DNA Top1 attracts the interests of research community as a cancer chemotherapy 
target [88]. Efforts to overcome side effects of these clinically used anticancer Top1 
inhibitors, particularly bladder toxicity, had led to the development of luotonin A 
alkaloid and discovery of its Top1 inhibitory activity [89].
Ibric et al. reported the development of novel luotonin A isomeric conge-
ners bearing an amino at positions 1, 2, 3, and 4, (93–97) Figure 14 [90]. These 
compounds revealed significant profile of cytotoxic activity and G2/M cell cycle 
arrest, proposing either Top1 is not the only target, or some atypical mechanism is 
accountable for inhibition of Top1 enzyme.
Khadka et al. [91]. synthesized 2-arylquinazolinone derivatives (98–100) to 
investigate these compounds as effective, safe, and selective cytotoxic agents target-
ing topoisomerases (topos). These compounds showed superior potency as topo 
I-inhibitors but were inactive against topo IIa.
Kamata et al. have prepared series of pyrimidoacridones (101), 
Pyrimidocarbazoles (102) and pyrimidophenoxadines (103) (Figure 14), and 
as topoisomerase II inhibitors [92]. Against P388 and KB cell lines, pyrimidocar-
bazoles and pyrimidophenoxadines were more potent than pyrimidoacridines. 
Pyrimidocarbazoles inhibited the in vivo tumor growth of mouse sarcoma M5076 
with T/C values of 42% at 3.13 mg/kg/d, and increased the level of DNA-topo II 
cross-linking in P388 cells.
3.9 α-Glucosidase inhibitor activity
Diabetes is a reduced ability to convert glucose into energy inside the body. 
The role of insulin is the glucose transfer from blood into cells. A large number of 
antidiabetic agents with different mechanism of action are available in the market.
Saeedi M et al. [93] reported a series of quinazolinone-1,2,3-triazole hybrids 
10a-p as potent α-glucosidase inhibitors for use as anti-diabetic agents that exhibited 
Figure 14. 
Chemical structure of topoisomerase enzyme inhibitors.
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more potent inhibitory activity against yeast α-glucosidase (IC50 181.0–474.5 μM) 
than reference drug acarbose (IC50 = 750.0). From these compounds, quinazoli-
none-1,2,3-triazoles possessing 4-bromobenzyl moiety connected to 1,2,3-triazole 
ring (104, 105; Figure 15) demonstrated the most potent α-glucosidase inhibitor 
activity. Triazoloquinazoline compounds (106–110; Figure 15) were reported as 
highly potent inhibitor of α-glucosidase enzyme (IC50 = 12.70 ± 1.87, 28.54 ± 1.22, 
45.65 ± 4.28, 72.28 ± 4.67 and 83.87 ± 5.12 μM, respectively) compared with the 
reference standard acarbose (IC50 = 143.54 ± 2.08 μM) [94].
Javaid et al. [95] reported a quinazolinone derivative (111; Figure 15) with IC50 
value of 0.3 ± 0.01 μM which is about 2800-fold more potent than acarbose refer-
ence standard drug. Rahman et al. [96] synthesized a series of hybrid compounds 
consisting of N-substituted-(4-oxo-2-substituted-phenylquinazolin-3-(4H)-yl) sub-
stituted benzene sulfonamide derivatives. From this series, compounds (112–116; 
Figure 15) explored significant antidiabetic activity.
3.10 Thymidine synthase inhibitor activity
Thymidylate synthase enzyme (TS) plays a crucial role in the DNA biosynthe-
sis that it catalyzes the conversion of deoxyuridine monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP), one of the nucleotides that constitute 
the DNA. Inhibition of TS results in imbalance of deoxynucleotides that increase 
the level of dUMP and finally leads to DNA damage [97]. TS is considered as inter-
esting chemotherapeutic target for treatment of pancreatic, colorectal, ovarian, 
breast and gastric cancers [98].
In 1998, raltitrexed (117) a quinazolin-4-(1H)-one compound that has been 
clinically approved by EMA for treatment of colorectal cancer. Also, pemetrexed 
Figure 15. 
Chemical structure of compounds with α-glucosidase inhibitor activity.
Quinazolinone and Quinazoline Derivatives
16
(118) is a quinazolin-4(1H)-one compound that is clinically approved by EMA and 
FDA in 2001. Both raltitrexed and pemetrexed are considered as classical antifo-
lates as they are folate analogs containing a pterin ring and a charged glutamate 
tail, therefore they need active internalization into the cells through folate carrier 
system [99].
In recent studies, El-Messery SM et al. [100] synthesized a series of 2,3,6-sub-
stituted quinazolin-4(3H)-ones. Of these compounds, compound (119; Figure 16) 
is the most potent inhibitor of bovine liver DHFR (with IC50 = of 0.02 μM). It was 
reported that 2-mercaptoquinazolin-4(3H)-one derivative is a potent bovine liver 
DHFR inhibitor (120; Figure 16) (IC50 = 0.01 μM) [101]. Javaid and co-workers 
[102] reported a series of 25 2-arylquinazolin-4(3H)-ones as potent thymidine 
phosphorylase inhibitors among these derivatives compounds (121, 122; Figure 16) 
were identified as the lead compounds (IC50 = 42.9 ± 1.0 and 59.5 ± 1.9 μM, 
respectively).
3.11 Monoamine oxidase inhibitor activity (MAO)
In human, monoamine oxidases (MAOs) are mitochondrial bound enzymes that 
are responsible for oxidative deamination metabolism of neurotransmitters such 
as dopamine, serotonin, norepinephrine and epinephrine. In the brain, MAO-A 
enzyme isoform metabolizes serotonin, therefore specific MAO-A inhibitors are 
used the treatment of anxiety and depression disorder [103]. On the other hand, 
MAO-B enzyme metabolizes dopamine in the brain thus MAO-B specific inhibitors 
are prescribed for the treatment of Parkinson’s disease [104].
Quinazolinone moiety, one of numerous MAO inhibitor scaffolds, it has 
been explored as lead for the further development of potent MAO inhibitors. 
Compounds (123–127; Figure 17) are representative MAO-inhibitor examples of 
4(3H)-quinazolinones [105].
Qhobosheane et al. reported seven quinazolinone compounds (IC50 < 1 μM) 
ascertained as potent and specific MAO-B inhibitors, among them the most potent 
inhibitor, 2-[(3-iodobenzyl)thio]quinazolin-4(3H)-one (128; Figure 17), with 
IC50 value of 0.142 μM. Although these derivatives have been proved as reversible 
and competitive MAO-B inhibitor (Ki = 0.068 μM), none of the them were MAO-A 
inhibitors [106].
Figure 16. 
Thymidine synthase and phosphorylase inhibitors.
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Khattab et al. [107] reported a series of quinazolinone bearing amino acid ester 
or amino acid hydrazides (129–131; Figure 17) that revealed competitive higher 
inhibitory activity toward MAO-A than MAO-B. The anti-MAO-A activity were 
comparable with that of the standard reference clorgyline (IC50 = 2.9 × 10−9 M). 
Compounds (130, 131) were the most selective MAO-A inhibitors with selectiv-
ity index of 131 (SI = 39,524) superior to that of the reference drug clorgyline 
(SI = 33,793).
4. Marketed quinazolinone drugs
Proquazone is non-steroidal anti-inflammatory drug (Biarison®) (132; 
Figure 18) manufactured by Novartis pharmaceutical company. Also, it is used in 
the treatment of degenerative joint disease.
Nolatrexed [108] compound (133; Figure 18) is a thymidylate synthase inhibi-
tor drug manufactured by Agouron pharmaceutical company under trade name 
Thymitaq®. In 1998, Zarix licensed Thymitaq® from Agouron. It is used in treat-
ment of liver cancer.
Quinethazone or Hyromox® [109] (134; Figure 18) has been marketed as anti-
hypertensive drug by Lederle pharmaceutical company and was recently withdrawn 
from the market.
Fenquizone’s brand name is Idrolone® (135; Figure 18) [110], it is marketed by 
Maggioni pharmaceutical company. It is a low-ceiling diuretics used in the treat-
ment of oedema and hypertension.
The brand name of albaconazole [111] is Albaconazole® (136; Figure 18). It 
was marketed by GlaxoSmithKlyne pharmaceutical company as an oral and topical 
antifungal agent.
Febrifugine, Dichroin B® or ChangShan® (137; Figure 18) [112] was isolated 
from Chinese herb Dichroa febrifuga as potent antimalarial drug and was marketed 
by Hawaii Pharm pharmaceutical company.
Figure 17. 
Chemical structure of monoamine oxidase (MAO) inhibitors.
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The brand name of afloqualone is Arofuto® (138; Figure 18) [113]. It is mar-
keted by Mitsubishi Tanabe Pharma pharmaceutical company as sedative and 
muscle relaxant drug.
Evodiamine (139; Figure 18) [114] has been isolated from the Evodia plants and 
was found to reduce fat uptake in animal model. It is used for bodybuilding as over 
the counter supplements.
5. Conclusions
This chapter depicts different methods of synthesis of quinazolinone derivatives 
starting from affordable and easily accessible substrates including 2-aminobenzoic 
acid, 2-aminobenzamide, o-substituted aniline in addition to the synthetic methods 
of spiroquinazolinones and heterocycle-fused quinazolinones. Also, the chapter 
discusses different biological applications of both natural and synthetic quinazoli-
nones. The last section in this chapter lists common quinazolinone drugs that have 
been approved in the market.
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